JeanMarie Guenot, PhD., is the President and Chief Executive Officer of Amphivena Therapeutics Inc. The company started its operations in July 2013 and is dedicated to the development of innovative therapies specifically for hematologic malignancies. The San Francisco based company is a preclinical stage based Research Company and its Research and Development team is in the process of development of a first-in-class bi-functional antibody therapy to address the blood cancer indications with high unmet medical needs. Amphivena Therapeutics, Inc. has a motto that aptly summarizes the mission of the company which reads “Restoring the flow of life.”
JeanMarie has tremendous expertise in many fields including venture capital, project and alliance management, corporate and commercial development, business development, and pharmaceutical research and development. Her experience spans through all stages of company development in both private and public companies. JeanMarie got her PhD. from University of California, San Francisco in 1993after which she joined Hoffman- La Roche as the Team Leader/ Principal Scientist of Preclinical Research and Development department, a position whose roles involved the discovery and development of drugs for inflammation, metabolic diseases, oncology and autoimmune diseases. She stayed in this position until 1999 and in 2000 she joined Atlas Venture, a venture capital and private equity firm where she held the position of Associate in Life Sciences.
As per her website GuenotLLC.com, JeanMarie left Atlas Venture in 2003 and joined PDL Biopharma, a biotechnology firm, as Vice President of Corporate and Business Development. At PDL she was in charge of licensing, mergers and acquisitions and alliance management for the Research and Development department. She remained in this position until 2008 when she became Managing Partner at Guenot LLC. In 2009, JeanMarie was working at SKS Ocular, LLC. At SKS Ocular, she was a Founder, Partner, and First Employee, where she focused on ophthalmology as the key Operating Officer up until 2012.
As CEO of Amphivena Therapeutics, JeanMarie has overseen the milestones surpassed by the Research and Development Department with the latest news concerning Acute Myeloid Leukemia. The company has focused on using tetravalent bispecific CD33/CD3 TandAbs for in vivo and in vitro killing of Acute Myeloid Laukemia.
JeanMarie Guenot’s achievements have received the recognition they deserve and in 2005 she received the BioBusiness Network’s Innovative Bio-Partnering Award and in 2006 the Licensing Executives Society awarded her the Deal of Distinction. Under Guenot’s capable leadership, Amphivena Therapeutics is making headway in providing cutting edge development research aimed at blood cancer, a disease that takes a toll on those afflicted and this effort is commendable and deserves more recognition.